

CLAIMS

What is claimed is:

1. A method of generating an infectious clone, said infectious clone based upon a positive strand RNA virus's genome, said method comprising:

producing a recombinant nucleic acid comprising at least one full-length DNA copy or at least one *in vitro*-transcribed RNA copy or a derivative of either said at least one DNA copy or said at least one *in-vitro* transcribed RNA copy,

wherein the RNA virus's genome is at least about 15 kb.

2. A method of generating an infectious clone based upon an RNA virus's genome, said method comprising:

producing a recombinant nucleic acid comprising at least one full-length DNA copy or *in vitro*-transcribed RNA copy or a derivative of either, and

selecting infectious clones by transfecting a host cell with said recombinant nucleic acid wherein said host cell is not susceptible to infection to said virus.

3. The method according to claim 2 wherein said RNA virus is a positive strand RNA virus with a genome of at least about 15 kb.

4. The method according to claim 2 wherein said host cell is a BHK-21 cell.

~~5. A modified RNA virus comprising a recombinant nucleic acid, said recombinant nucleic acid comprising at least one full-length DNA copy or *in vitro*-transcribed RNA copy or a derivative of either.~~

6. A vaccine comprising a modified RNA virus, said modified RNA virus comprising a recombinant nucleic acid which comprises at least one full-length DNA copy or *in vitro*-transcribed RNA copy or a derivative of either.

7. A cell culture infected with a modified RNA virus, said modified RNA virus comprising a recombinant nucleic acid which comprises at least one full-length DNA copy or *in vitro*-transcribed RNA copy or a derivative of either.

8. A protein and/or antigen obtained from a cell culture according to claim 7.

9. A diagnostic assay using a protein and/or antigen of claim 8, said assay useful for diagnosis in an animal vaccinated with a vaccine based on the modified RNA virus.

10. A recombinant nucleic acid comprising an infectious clone produced by the method according to claim 1.

11. The recombinant nucleic acid of claim 10 wherein the infectious clone is based on the genome of a virus of the order *Nidovirales*.

12. The recombinant nucleic acid of claim 11 wherein the infectious clone is based on the genome of a virus of the family *Arteriviridae*.

13. The recombinant nucleic acid of claim 12 wherein the virus is PRRSV.

14. The recombinant nucleic acid molecule of claim 10 wherein the infectious clone further comprises at least one nucleic acid sequence encoding a virulence marker and/or a serological marker particular to said positive strand RNA virus, and wherein said at least one nucleic acid sequence has been modified to effect a change in virulence and/or a change in serological immune response *in vivo*.

15. The recombinant nucleic acid molecule of claim 14 wherein the nucleic acid sequence encoding said virulence or serological marker or virulence and serological markers is located within any of the genome's open reading frames encoding structural viral proteins.

16. The recombinant nucleic acid molecule of claim 10 wherein said infectious clone further comprises a nucleic acid sequence comprising at least one open reading frame and wherein said at least one open reading frame is substituted by an ORF7.

17. The recombinant nucleic acid molecule of claim 10 wherein at least one additional heterologous nucleic acid sequence is inserted, allowing the infectious clone to serve as a delivery system for an additional heterologous nucleic acid sequence.

18. The recombinant nucleic acid molecule of claim 17 wherein said heterologous nucleic sequence encodes an antigen.

19. The recombinant nucleic acid molecule of claim 10 wherein said infectious clone further comprises a nucleic acid sequence comprising at least one open reading frame, said at least one open reading frame having been modified to effect a change in virulence and/or a change in serological response *in vivo* in a cell into which the infectious clone has been introduced.

20. A modified RNA virus comprising the recombinant nucleic acid of claim 10.

21. A vaccine comprising the modified RNA virus of claim 20.
22. A cell culture infected with the modified RNA virus of claim 20.
23. A protein and/or antigen obtained from a cell culture according to claim 22.
24. A diagnostic assay using a protein and/or antigen of claim 23, said assay useful for diagnosis in an animal vaccinated with a vaccine based on the modified RNA virus.

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99
00000	00001	00002	00003	00004	00005	00006	00007	00008	00009	00010	00011	00012	00013	00014	00015	00016	00017	00018	00019	00020	00021	00022	00023	00024	00025	00026	00027	00028	00029	00030	00031	00032	00033	00034	00035	00036	00037	00038	00039	00040	00041	00042	00043	00044	00045	00046	00047	00048	00049	00050	00051	00052	00053	00054	00055	00056	00057	00058	00059	00060	00061	00062	00063	00064	00065	00066	00067	00068	00069	00070	00071	00072	00073	00074	00075	00076	00077	00078	00079	00080	00081	00082	00083	00084	00085	00086	00087	00088	00089	00090	00091	00092	00093	00094	00095	00096	00097	00098	00099	